← Leaderboards
R. Brad Jones
Massachusetts Institute Of Technology
$33,846,824
Attributed
$62,392,693
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10.7M · FY2016–25$20M$15M$10M$5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$62,392,693 · 18
By mechanism
UM1$41,717,690 · 3
R01$12,806,654 · 5
R33$3,037,329 · 2
R21$2,268,114 · 5
R37$1,693,900 · 1
R56$743,679 · 1
Top collaborators
- Conrad Russell Young Cruz10 shared
- Darrell J Irvine8 shared
- Marina Caskey6 shared
- Rohan Fernandes5 shared
- Neville Sanjana3 shared
- Frederic D Bushman2 shared
- Robert H Miller2 shared
- Douglas F Nixon2 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsVirusInfectionPharmaceutical PreparationsCd4 Positive T LymphocytesIn VivoAdherenceViralImmune SystemHiv InfectionsImmuneAnti-Retroviral AgentsAntiretroviral TherapyMediatingViral ReservoirIn VitroPersonsCytotoxic T-LymphocytesClinical TrialsModernizationNeutralizing AntibodyT-LymphocyteResponseMouse Model
Grant awards (48)
REACH: Research Enterprise to Advance a Cure for HIV$5,432,259
UM1 · FY2025 · AI · contact PI
INSPIRE: Innovative Strategies for Personalized Immunotherapies and Reservoir Eradication$2,948,452
UM1 · FY2025 · AI · contact PI
Defining and then Maximizing the Footprint of CTL Selection on HIV Integration Site Landscapes to Optimize Cure Strategies$829,575
R37 · FY2025 · AI · contact PI
Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational Approach$770,236
R01 · FY2025 · AI · contact PI
Mechanisms of CTL Resistance in HIV Reservoirs$708,526
R01 · FY2025 · AI · contact PI
REACH: Research Enterprise to Advance a Cure for HIV$5,371,650
UM1 · FY2024 · AI · contact PI
Defining and then Maximizing the Footprint of CTL Selection on HIV Integration Site Landscapes to Optimize Cure Strategies$864,325
R37 · FY2024 · AI · contact PI
Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational Approach$827,457
R01 · FY2024 · AI · contact PI
Mechanisms of CTL Resistance in HIV Reservoirs$708,526
R01 · FY2024 · AI · contact PI
REACH: Research Enterprise to Advance a Cure for HIV$5,567,406
UM1 · FY2023 · AI · contact PI
Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational Approach$862,207
R01 · FY2023 · AI · contact PI
Mechanisms of CTL Resistance in HIV Reservoirs$800,474
R01 · FY2023 · AI · contact PI
Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirs$763,694
R01 · FY2023 · AI · contact PI
A participant-derived xenograft mouse model to study T-cell-mediated viral control and mRNA vaccine strategies$211,875
R21 · FY2023 · AI · contact PI
REACH: Research Enterprise to Advance a Cure for HIV$5,478,120
UM1 · FY2022 · AI · contact PI
Mechanisms of CTL Resistance in HIV Reservoirs$812,001
R01 · FY2022 · AI · contact PI
Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirs$774,058
R01 · FY2022 · AI · contact PI
Biomaterials-Enhanced NK Cells for Improved Elimination of the HIV Reservoir$485,681
R33 · FY2022 · AI
A participant-derived xenograft mouse model to study T-cell-mediated viral control and mRNA vaccine strategies$254,250
R21 · FY2022 · AI · contact PI
REACH: Research Enterprise to Advance a Cure for HIV$5,683,679
UM1 · FY2021 · AI · contact PI
Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirs$784,154
R01 · FY2021 · AI · contact PI
Biomaterials-Enhanced NK Cells for Improved Elimination of the HIV Reservoir$485,681
R33 · FY2021 · AI
CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional Characteristics$423,750
R01 · FY2021 · AI · contact PI
Characterization of a Memory CD4+ T-cell Humanized Mouse Model for the Evaluation of Autologous Cell Therapies and Studies of HIV Persistence$211,875
R21 · FY2021 · AI · contact PI
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication$5,680,664
UM1 · FY2020 · AI
Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirs$793,988
R01 · FY2020 · AI · contact PI
Defining & Characterizing Novel Mechanisms by which HIV-infected Primary CD4+ T-cells Intrinsically Resist Elimination by CTL$743,679
R56 · FY2020 · AI · contact PI
Biomaterials-Enhanced NK Cells for Improved Elimination of the HIV Reservoir$516,359
R33 · FY2020 · AI
Engineered CTL with Inducible Ab Secretion; a Tripartite attack on HIV Reservoirs$508,277
R33 · FY2020 · AI · contact PI
CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional Characteristics$423,750
R01 · FY2020 · AI · contact PI
Characterization of a Memory CD4+ T-cell Humanized Mouse Model for the Evaluation of Autologous Cell Therapies and Studies of HIV Persistence$254,250
R21 · FY2020 · AI · contact PI
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication$5,555,460
UM1 · FY2019 · AI
Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirs$838,922
R01 · FY2019 · AI · contact PI
Engineered CTL with Inducible Ab Secretion; a Tripartite attack on HIV Reservoirs$510,760
R33 · FY2019 · AI · contact PI
CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional Characteristics$423,750
R01 · FY2019 · AI · contact PI
Biomaterials-Enhanced NK Cells for Improved Elimination of the HIV Reservoir$200,479
R21 · FY2019 · AI
Engineered CTL with Inducible Ab Secretion; a Tripartite attack on HIV Reservoirs$530,571
R33 · FY2018 · AI · contact PI
CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional Characteristics$423,750
R01 · FY2018 · AI · contact PI
T-cell-mediated targeting of therapeutics to HIV reservoirs$422,887
R01 · FY2018 · AI
Biomaterials-Enhanced NK Cells for Improved Elimination of the HIV Reservoir$234,084
R21 · FY2018 · AI
T-cell-mediated targeting of therapeutics to HIV reservoirs$422,887
R01 · FY2017 · AI
CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional Characteristics$398,750
R01 · FY2017 · AI · contact PI
Assessing the CNS as a source of HIV rebound, and evaluating strategies for immune-mediated reservoir elimination$235,893
R21 · FY2017 · MH
Engineered CTL with Inducible Ab Secretion; a Tripartite attack on HIV Reservoirs$203,533
R21 · FY2017 · AI · contact PI
T-cell-mediated targeting of therapeutics to HIV reservoirs$422,887
R01 · FY2016 · AI
Engineered CTL with Inducible Ab Secretion; a Tripartite attack on HIV Reservoirs$262,500
R21 · FY2016 · AI · contact PI
Assessing the CNS as a source of HIV rebound, and evaluating strategies for immune-mediated reservoir elimination$199,375
R21 · FY2016 · MH · contact PI
Acquisition of the BioRad QX200 AutoDG Droplet Digital PCR System$125,327
S10 · FY2016 · OD · contact PI